All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

European regulators approve Eli Lilly's Kisunla amyloid-targeting drug for early symptomatic Alzheimer's disease after appeal
Small molecule, neurological, Alzheimer's disease, monoclonal antibody, ARIA side effects - Read more

EMA approves AstraZeneca's Trixeo Aerosphere with eco-friendly propellant for chronic obstructive pulmonary disease treatment
Small molecule, respiratory disease, inhalation therapy, COPD, drug reformulation, environmental sustainability - Read more

Roche's Elecsys pTau181 blood test for Alzheimer's disease screening receives European regulatory approval
In vitro diagnostic, neurological, Alzheimer's disease, blood test, amyloid biomarker, tau protein - Read more

EU approves Sanofi's Sarclisa (anti-CD38) for newly diagnosed multiple myeloma in transplant-eligible patients following Ph3 success
Antibody, cancer, monoclonal antibody, multiple myeloma, combination therapy, newly diagnosed patients - Read more

Gilead's HIV prevention drug lenacapavir receives positive CHMP opinions, awaits final European Commission approval
HIV capsid inhibitor, infectious disease, regulatory approval, preventative medicine - Read more

Pfizer and BioNTech receive positive CHMP recommendation for LP.8.1-adapted COVID-19 vaccine in EU
mRNA vaccine, infectious disease, regulatory, operational - Read more

THE GOOD
Business Development & Partnerships

Hengrui Pharma, GSK partner on 12 innovative medicines across multiple therapeutic areas; $500M upfront payment
Licensing deal, co-development, respiratory, immunology, oncology, milestone payments - Read more

PRESENTED BY YOU?
Get the attention of 2000+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Memo Therapeutics' potravitug shows promising Ph2 results in kidney transplant recipients with BK polyomavirus nephropathy
Antibody, infectious disease, monoclonal antibody, BK polyomavirus, kidney transplant, viral neutralization - Read more

Kintor Pharmaceutical's KX-826 tincture hits Ph2 primary endpoint for male androgenetic alopecia treatment in 90-patient trial
Small molecule, dermatological, androgen receptor antagonist, alopecia, male pattern baldness, topical treatment - Read more

THE GOOD
Fundraises

Abivax raises $747.5M in public offering, developing immune modulators for inflammatory diseases
Chronic inflammatory diseases, clinical-stage, immunomodulation, platform technology, therapeutics - Read more

THE GOOD
Lawsuits

Sun Pharma and Taro settle generics price-fixing litigation for $200M
Generic drugs, financial, legal settlement, regulatory, antitrust - Read more

THE GOOD
Strategic Plans

Roche reaffirms gene therapy commitment despite Elevidys safety issues and industry challenges
Gene therapy, rare disease, strategic, operational - Read more

THE BAD
Approvals & Labels

FDA delays approval decision for Bayer's elinzanetant NK3 receptor therapy for menopause-related vasomotor symptoms pending additional review
Small molecule, women's health, non-hormonal therapy, menopause, vasomotor symptoms, NK3 inhibitor - Read more

THE BAD
Clinical Trials

Memo Therapeutics advances potravitug to Ph3 for BK polyomavirus nephropathy despite missing primary Ph2 endpoint
Antibody, infectious disease, monoclonal antibody, BK polyomavirus, kidney transplant, viral infection - Read more

Recognify's Ph2b trial for inidascamine misses primary endpoint in cognitive impairment associated with schizophrenia
Small molecule, neurological, schizophrenia, cognitive impairment, CIAS, Phase 2b - Read more

THE UGLY
Approvals & Labels

EMA rejects Roche's Duchenne muscular dystrophy gene therapy Elevidys targeting dystrophin in Ph3 setback
Gene therapy, neurological, Duchenne muscular dystrophy, dystrophin, pediatric patients - Read more

THE UGLY
Lawsuits

Lawsuit alleges Amgen-acquired ChemoCentryx doctored Tavneos trial data, ignored monitoring committee warnings
Small molecule, autoimmune, rare disease, regulatory, ethical misconduct, litigation - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here